- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05847179
Fase 2, studio in aperto per valutare la sicurezza e la tollerabilità della progerinina nella sindrome di Werner
Uno studio di fase 2 in aperto per valutare la sicurezza e la tollerabilità della progerinina per il trattamento della perdita di densità minerale ossea (BMD) in soggetti con la tipica sindrome di Werner
This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.
There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.
Panoramica dello studio
Descrizione dettagliata
Subjects who have successfully completed the Screening phase will enter the baseline and treatment phase of the study. Subjects will take the assigned treatment of Progerinin (2400 mg) split as 1200 mg BID in the morning and evening with food for 1-Year.
To evaluate the safety and tolerability of Progerinin for the treatment of BMD loss in subjects with typical Werner syndrome.
The secondary objectives of this study are:
- To characterize the activity of Progerinin on bone metabolism in subjects with typical Werner Syndrome.
- To evaluate vascular function in subjects with typical Werner Syndrome.
- To evaluate glucose metabolism and insulin resistance in subjects with typical Werner Syndrome.
- To evaluate lipid metabolism in subjects with typical Werner Syndrome.
- To evaluate physical function in subjects with typical Werner Syndrome.
- To evaluate the pharmacokinetics (PK) of Progerinin sachet administered twice daily (BID) in subjects with typical Werner Syndrome.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Christine Lee
- Numero di telefono: 301-540-2600
- Email: christinelee@kcrnresearch.com
Luoghi di studio
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- University of Michigan
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
[Inclusion Criteria]
-
Subjects must be at least ≥ 18 years of age.
-
Subjects should have a confirmed diagnosis of typical Werner syndrome by genetic analysis.
-
Subjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (T-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.
-
Male or non-pregnant, non-lactating female.
-
Subjects screening blood chemistry inclusive of metabolic panel, hematology, and urine analysis results should be acceptable to the investigator.
-
Negative pregnancy test for female subjects as described below. Women of child bearing potential (WOCBP) and Women not of child-bearing potential are eligible to participate. Both women of childbearing potential and women of non-child-bearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study and for 90 days after last treatment.
Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or two years post-menopausal. All male subjects/partners must agree to use a In addition, subjects may not donate sperm for the duration of the study and for 90 days after last treatment.
Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test at baseline within the one (1) week prior to the first study medication administration. Every six weeks, and at study termination a pregnancy test should be performed, either serum or urine stick test. However, if the urine result is positive, a serum pregnancy test will be performed.
-
Provide signed written informed consent and willingness, ability to comply with study requirements.
-
Subject must have a projected life expectancy of ≥ 12 months in the opinion of the Investigator.
[Exclusion Criteria]
-
Subject with clinical signs seen at screening are at the final stage of Werner syndrome progression, and completion of the study is difficult to be assessed, including:
- Subjects who received continuous or intermittent home oxygen therapy for 6 months before obtaining consent
- Subjects who received at least 2 hospitalizations for pneumonia during the 12 months prior to obtaining consent
- Subjects who have at least 10% net weight loss and have not recovered. This includes significant net weight loss over the last six months.
-
Subjects with significant dehydration as judged by the principal investigator.
-
Subjects with pericardial fluid, ascites and pleural effusion.
-
Therapy with investigational drugs within 30 days of beginning study medication.
-
History of prior malignancy, except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (e.g., breast, prostate) for which the subject has been disease-free for at least 3 years.
-
Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for the study.
-
Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous (IV) treatment for infection(s).
-
Subjects with known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV).
-
Subjects with a history of serious drug hypersensitivity or allergic reaction such as anaphylaxis or any component of the formulation.
-
Clinically significant bleeding within 2 weeks prior to baseline (e.g., gastrointestinal [GI] bleeding, intracranial hemorrhage).
-
Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.
-
Pregnant or lactating women.
-
Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy), within 28 days prior to baseline or anticipated surgery during the study period.
-
Inability to return for scheduled treatment and assessments.
-
Subjects that require concomitant use of any medications or substances that are strong inhibitors or inducers of CYP2D6 or CYP2C8
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Treatment Group
all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year |
This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. . There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
The intensity of the event will be graded using CTCAE v6.0 criteria |
Baseline to Week 56 (including 4-week follow-up)
|
|
Incidence of Treatment-Related Adverse Events
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Incidence of Serious Adverse Events (SAEs)
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Incidence of TEAEs and SAEs leading to discontinuation of study medication
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Blood Chemistry from Baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Hematology from Baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Urinalysis Results from Baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Height (cm) from Baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Weight (kg) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Temperature (°C) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Pulse Rate (beats per minute) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Respiratory Rate (breaths per minute) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Systolic Blood pressure (mmHg) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Diastolic Blood pressure (mmHg) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Physical Examination findings from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG Ventricular Rate (beats per minute) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG PR interval (msec) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QRS interval (msec) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QT interval (msec) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QTc interval (msec) from baseline
Lasso di tempo: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Change in Femur Bone Mineral Density (BMD) from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Lumbar Spine BMD from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Aortic Pulse Wave Velocity (m/s) from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Lipid Profile from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Handgrip Strength Test from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Short Physical Performance Battery (SPPB) Total Score from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Ankle-Brachial Pressure Index (ABPI) from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Bone-Specific Alkaline Phosphatase (BAP) from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Osteocalcin (OC) from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Procollagen Peptides (P1NP) from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Deoxypyridinium (DPD) from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baseline
Lasso di tempo: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Pharmacokinetic Parameters of Progerinin at the Specified PK Assessment Visits
Lasso di tempo: Baseline, Week12, Week 24, Week 36 and Week 52
|
Baseline, Week12, Week 24, Week 36 and Week 52
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- PRG-PRO-004
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .